St. Luke’s University Health Network (SLUHN) will expand its participation in clinical trials for cancer research though an innovative partnership with Rutgers Cancer Institute of New Jersey, the only National Cancer Institute-designated Comprehensive Cancer Center in New Jersey, together with RWJBarnabas Health.
“This unique partnership is great for St. Luke’s cancer patients, and it’s great for cancer research. It will allow St. Luke’s to provide patients with greater access to a larger portfolio of cancer clinical trials beyond those offered within our own institution,” said Dr. Israel Zighelboim, St. Luke’s chairman of oncology. “It also opens the door to collaborate on various other cutting edge cancer research activities being conducted at Rutgers Cancer Institute. This is a major competitive advantage for St. Luke’s patients.”
As an NCI-designated Comprehensive Cancer Center, Rutgers Cancer Institute is known for excellence in cancer research, prevention and care, including clinical trials.
Rutgers Cancer Institute members collaborate with industry and other academic centers to conduct basic, clinical and population research for both adult and pediatric cancer patients. Areas of investigation include cellular therapy, precision medicine, immunotherapy, epidemiology, chemical carcinogens, tumor virology and immunology, drug development and resistance, and cancer genomics.
In 2019, St. Luke’s signed a collaborative agreement with RWJBarnabas Health, New Jersey’s largest academic health system. This arrangement with Rutgers Cancer Institute is the latest benefit from the positive relationship between RWJBarnabas Health and St. Luke’s.
Join our readers whose generous donations are making it possible for you to read our news coverage. Help keep local journalism alive and our community strong. Donate today.
